RECHERCHE :   Tumeurs solides avancées
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
BMS CA022-001: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
Tumeurs solides avancées
I, II
CHUV
BMS CA224-020 - A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Mélanome
I
CHUV
CA027-002: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers
Tumeurs solides avancés
I, II
CHUV
BMS CA224-048: A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Tumeurs solides (Mélanome, Cancer du poumon non à petites cellules (NSCLC))
I, II
CHUV
MK7339-002 : A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
II
HUG
CHUV-DO-0018-NeoTIL-2019: Pilot Study to Assess the Feasibility, Safety and Efficacy of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes Enriched for Tumor Antigen Specificity (NeoTIL) in Advanced Solid Tumors.
Tumeurs solides
I
CHUV
PH- IL12L19L19-01/19: A phase I study to evaluate safety and early signs of efficacy of the human monoclonal antibody-cytokine fusion protein IL12-L19L19.
Advanced or metastatic carcinomas and diffuse large B-cell lymphoma
I
HUG
SGNB6A-001: A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
NSCLC, HNSCC, ESCC, HGSOC, cSCC, cancer du sein HER2 négative avancé, adénocarcinome pancréatique exocrine, cancer de la vessie, cancer degestif, cancer du col de l'utérus
I
CHUV
T3P1001: An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumours
Tumeurs solides de stade avancé
I, II
CHUV